All publications

Impact of hot and wet granulation techniques on Compritol® 888 ATO lipid matrices for extended release of highly water soluble high dose API

  • Poster

CRS Annual Meeting – Seattle (2016)  - 2016

Ketkee Deshmukh, Chhanda Kapadia, Agnivesh Shrivastava, Gayatri Khanvilkar, Pradnya Vaingankar and Purnima Amin

The poster describes the formulation of sustained release tablets with Metformin HCl (a well-known oral antihyperglycemic) using Compritol® 888 ATO as a sustained release agent. Different granulation techniques were evaluated to elucidate the impact of formulation and process on tablet properties and drug release. The objective was to determine a simple process that enables the production of ‘smaller’ tablets, using less excipients, whilst maintaining therapeutic drug dose and obtaining drug release which passes Pharmacopeial specifications. 

Download (.pdf - 3.02 MB)

Influence of Formulation Factors and Compression Force on Release Profile of Sustained Release Metoprolol Tablets using Compritol® 888 ATO as Lipid Excipient

  • Scientific publication

Indian J Pharm Sci 2015;77(5): 620-625 - Sep 2015

Shilpa N. PATERE, Chhanda J. KAPADIA and Mangal S. NAGARSENKER

Release profile of metoprolol from sustained release tablets using Compritol® 888 ATO as SR lipid matrix agent showed high reliability. Different sources of active ingredient and batches of Compritol® were evaluated at different compression forces and in dissolution media containing or not ethanol. The formulation appeared to be very robust and is not affected by these variables. Therefore Compritol® offers great potential in the formulation of reliable SR tablets.

New insights into the stability of SR lipid matrix tablets

  • Poster

CRS Annual Meeting – Edinburgh (Scotland) - Jul 2015

Y. Rosiaux, V. Jannin, J. Doucet, J-M. Girard, F. Desvignes, and D. Marchaud

Download (.pdf - 769.35 KB)

Exploring the possible relationship between the drug release of Compritol®-containing tablets and its polymorph forms using micro X-ray diffraction

  • Scientific publication

Journal of Controlled Release, Volume 197, Pages 158-164 https://doi.org/10.1016/j.jconrel.2014.11.013 - Jan 2015

Vincent Jannin; Stéphanie Chevrier; Cédric Miolane; Margaux Metin; Hamza Benhaddou; Yann Chavant; Fred Monsuur; Frédéric Demarne

Ethanol resistant extended release matrix tablets with Compritol® 888 ATO

  • Poster

AAPS Annual Meeting and Exposition – San Diego (USA)  - Nov 2014

Yvonne Rosiaux, Jean-Michel Girard, Florence Desvignes, Cédric Miolane, Delphine Marchaud

Effect of Tablet Structure on Controlled Release from Supersaturating Solid Dispersions Containing Glyceryl Behenate.

  • Scientific publication

Mol. Pharmaceutics, 2015, 12 (1), pp 120–126 DOI: 10.1021/mp500480y - Oct 2014

Justin M. Keen, Justin R. Hughey, Ryan C. Bennett, Vincent Jannin, Yvonne Rosiaux, Delphine Marchaud, and James W. McGinity

Estimating in vivo drug release from a new theophylline Compritol® 888 ATO matrix formulation using appropriate biorelevant test methods

  • Poster

CRS Annual Meeting – Chicago (USA)  - Jul 2014

N. Fotaki, C. M. Long, Y. Rosiaux, D. Marchaud, Grzegorz Garbacz, S. Lange and S. Klein

Streamlining the design of sustained release matrix tablets using mathematical modeling for drug release optimization

  • Poster

CRS Annual Meeting – Chicago (USA)  - Jul 2014

Y. Rosiaux, F. Desvignes, JM. Girard, C. Miolane, S. Hughes and D. Marchaud

Smart strategies for sustained release matrix tablets: Compritol® 888 ATO

  • Whitepaper

OutsourcingPharma - May 2014

Gattefossé

This white paper gives an overview of how Compritol® 888 ATO provides clinically relevant sustained drug release profiles along with biopharmaceutical, formulation and manufacturing advantages.